Your session is about to expire
← Back to Search
Palbociclib for Breast Cancer
Study Summary
This trial is testing a new cancer drug in women with a certain type of breast cancer.
- Breast Cancer
- Tumors
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 55 Patients • NCT03007979Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What medical condition is Palbociclib typically prescribed for?
"Palbociclib is the primary drug of choice for treating malignant neoplasms. It may also be used in other medical scenarios, including those involving ovarian cancer, ovulation induction therapy and high-risk patients."
How many medical facilities have adopted this trial to their research agenda?
"Patients can enrol in this trial at University of Wisconsin-Madison, Pennsylvania's Penn State Cancer Institute in Hershey, the University of Illinois Cancer Center located in Chicago and 7 other sites situated throughout the US."
How many patients have been selected to partake in this trial?
"This particular investigation is not presently enrolling participants. It was originally advertised on June 30th, 2016 and last edited on August 29th 2022. If you are looking for alternative studies, there are 4,533 trials that seek cancer patients and 192 studies searching for Palbociclib candidates."
Are there any previous experiments that have utilized Palbociclib?
"Currently, 192 Palbociclib studies are being conducted with 38 of those in the final phase. Of these trials, a majority are situated in Burgas, New jersey; however there exist 13808 total sites running clinical observations for this medication."
What are the core aims of this experiment?
"The primary objective of this three-year clinical trial is to assess response rates in subjects with HR(+)/HER2(-) advanced breast cancer who have yet to receive systemic anti-cancer treatments. Additionally, the study will evaluate adverse events and toxicity along with progression free survival and clinical benefit rate through RECIST 1.1 or MDA criteria for those with bone only disease."
To what extent could Palbociclib be detrimental to a person's health?
"There is limited clinical data available to support the safety of Palbociclib, thus Power assigned it a score of 2 on its scale."
Is this research endeavor actively seeking participants at present?
"The clinicaltrials.gov database has revealed that this experiment is currently not recruiting patients, despite being initially posted on June 30th 2016 and last edited on August 29th 2022. Nonetheless, there are 4,725 other medical trials actively searching for participants as of now."
Share this study with friends
Copy Link
Messenger